Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PR positive status confers therapeutic sensitivity to Letrozole in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the first-line treatment of patients who are postmenopausal women with hormone-dependent advanced breast cancer.
This statement is based on a regulatory approval from the Health Products Regulatory Authority:
First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.